Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.IMVT · Entity 3632 | Director | August 28, 2026 | August 28, 2026 |
| Sio Gene Therapies Inc.SIOX · Entity 130622 | Director | April 15, 2021 | April 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date August 28, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,731 |
Ending reported balance
After 2026-08-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-28 · Exercise / conversion · Acquired 1,500 · Balance 118,231 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. Row 2 · 2026-08-28 · Sale · Disposed 1,500 · Balance 116,731 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-11-19 | Direct | 65,181 |
Reported balance
After 2026-08-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-28 · Exercise / conversion · Disposed 1,500 · Balance 65,181 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025. F2: Reflects an award of stock options to purchase Common Shares that is fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 20,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
F2: Reflects an award of stock options to purchase Common Shares that is fully vested.
Sio Gene Therapies Inc.
Report date April 15, 2021 · Filed April 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2031-04-14 | Direct | 42,000 |
Reported balance
After 2021-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-15 · Grant · Acquired 42,000 · Balance 42,000 F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Karuna Therapeutics, Inc.
Report date March 18, 2024 · Filed March 18, 2024
Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 1
1 source rowRow 1 · 2024-03-18 · Disposition to issuer · Disposed 990 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.59 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-18 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.01 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-18 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.96 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-18 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.70 · Expires 2033-06-19 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-18 · Disposition to issuer · Disposed 1,904 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.
F4: These Options are fully vested.
F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2020 Filed Aug 14, 2020 20:16 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001593968-20-001751 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,714 Underlying: Common Stock · 5,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:16 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 5,000 | $85.00 | $425,000.00 |
DisclosureSEC source: 0001593968-20-001751 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:16 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 5,000 | $2.92 | $14,600.00 |
DisclosureSEC source: 0001593968-20-001751 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2020 Filed Jul 13, 2020 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001593968-20-001631 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,714 Underlying: Common Stock · 5,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2020 Filed Jul 13, 2020 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 5,000 | $95.43 | $477,150.00 |
DisclosureSEC source: 0001593968-20-001631 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 13, 2020 Filed Jul 13, 2020 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 5,000 | $2.92 | $14,600.00 |
DisclosureSEC source: 0001593968-20-001631 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 22:12 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | PurchaseCommon Shares | 10,000 | $2.73 | $27,290.00 |
DisclosureSEC source: 0001209191-20-042216 · doc4.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Atul C. Pande & Patricia A Pande TR DTD 08/24/2017 Disclosed balance after: 23,370 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.7075 to $2.73 per share, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 21:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001593968-20-001465 · primary_01.xml · derivative · entry 3 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,714 Underlying: Common Stock · 5,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 21:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 5,000 | $93.27 | $466,350.00 |
DisclosureSEC source: 0001593968-20-001465 · primary_01.xml · nonDerivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 21:19 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 5,000 | $2.92 | $14,600.00 |
DisclosureSEC source: 0001593968-20-001465 · primary_01.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:42 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 12,500 | $0.00 Strike: $97.59 | $0.00 |
DisclosureSEC source: 0001593968-20-001424 · primary_01.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 4, 2021, and (ii) the 2021 annual meeting of the Issuer's stockholders. Read SEC document |
| May 15, 2020 Filed May 18, 2020 12:47 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 37,000 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001209191-20-029941 · doc4.xml · derivative · entry 2 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2020-05-14 F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| May 15, 2020 Filed May 18, 2020 12:47 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 24,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029941 · doc4.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,700 F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation. F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation. Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 01:09 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001209191-20-025022 · doc4.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Shares · 17,500 shares Expires 2030-04-14 F1 · derivative.exercise_date: 100% of this option will vest on April 15, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| March 16, 2020 Filed Mar 19, 2020 00:20 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | PurchaseCommon Stock | 10,000 | $1.78 | $17,844.00 |
DisclosureSEC source: 0001209191-20-020125 · doc4.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Atul C. Pande & Patricia A Pande TR DTD 08/24/2017 Disclosed balance after: 13,370 F1 · price: The reported price in Column 4 is a weighted-average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.77 to $1.82 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 3,370 shares that were previously reported as directly owned. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:56 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 77,181 | Not disclosed Strike: $8.43 | Not disclosed |
DisclosureSEC source: 0001209191-19-061595 · doc4.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,181 Underlying: Common Stock · 77,181 shares Expires 2029-11-19 F2 · price: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 157,812 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC). F1 · derivative.exercise_date: This stock option vests over a period of three years, with 1/3 of the shares underlying the option vesting on each of the first, second and third anniversaries of the vesting commencement date. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 23:13 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-19-018720 · doc4.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2029-06-27 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 27, 2020, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 23:05 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | PurchaseCommon Stock | 3,370 | $5.22 | $17,595.44 |
DisclosureSEC source: 0001209191-19-037522 · doc4.xml · nonDerivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 01:21 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option ( Right to Buy) · Derivative | 255,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-19-025197 · doc4.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:34 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001209191-18-020375 · doc4.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2028-03-15 F1 · derivative.exercise_date: 100% of this option will vest on March 15, 2019, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| April 28, 2017 Filed May 3, 2017 01:01 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $24.24 | $0.00 |
DisclosureSEC source: 0001209191-17-029471 · doc4.xml · derivative · entry 1 Pande Atul · CIK 0001643071 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Shares · 27,000 shares Expires 2027-04-28 F1 · derivative.exercise_date: 100% of this option will vest one year after the date of grant. The option allows for early exercise, subject to the issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F2 · balance_after: Includes only options with the same termination date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.